This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
More than 200 residents, medical students and Fellow members have committed to volunteer for MBWS outreach events at universities, hospitals, and community venues, with a planned distribution of 10,000 gift bags with tips for managing winter skin and free moisturizing products generously provided by campaign sponsor, Clinique.
Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN.
A microneedle patch that delivers immune-regulating molecules may teach T cells not to attack hair follicles, helping regrow hair in alopecia areata, according to research in mice from MIT, Brigham and Women’s Hospital, and Harvard Medical School. This innovative approach marks a paradigm shift.
Ofir Cohn PhD , Boston Children’s Hospital, Boston, MA Deciphering how genetic variation associated with risk of eczema impacts human dendritic cell subset function Liwen Deng BS, PhD , President & Fellows of Harvard College, Boston, MA S.
Lawrence Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital-San Diego and Professor of Dermatology and Pediatrics and Vice-chair of the Department of Dermatology at UC San Diego School of Medicine, discusses innovations in topical and systemic therapies for atopic dermatitis in kids.
Elena Pope, MD, MSc of The Hospital for Sick Children, will conduct a project titled “ Kaposiform Hemangioendothelioma and Tufted angioma: To Treat or not to Treat, a retrospective multicenter cohort study.
Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Hospital in Detroit, explains how, when, and why she uses these new options. Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Hospital in Detroit, shares why she is so excited about the availability of Cabtreo (clindamycin phosphate 1.2%/adapalene
improved atopic dermatitis (AD) across all primary and secondary efficacy endpoints, with significant improvement as early as Week 1 on multiple efficacy endpoints in kids aged 2 to 5, according to the INTEGUMENT-PED Trial. Roflumilast cream 0.05% (Zoryve, Arcutis Biotherapeutics, Inc.) As previously reported, at Week 4, 25.4%
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content